Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $214.9 million.

  • Fulcrum Therapeutics' Liabilities and Shareholders Equity fell 2299.22% to $214.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $947.1 million, marking a year-over-year decrease of 1095.23%. This contributed to the annual value of $260.7 million for FY2024, which is 117.35% up from last year.
  • Fulcrum Therapeutics' Liabilities and Shareholders Equity amounted to $214.9 million in Q3 2025, which was down 2299.22% from $228.8 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Liabilities and Shareholders Equity registered a high of $321.1 million during Q1 2023, and its lowest value of $137.9 million during Q2 2021.
  • For the 5-year period, Fulcrum Therapeutics' Liabilities and Shareholders Equity averaged around $241.4 million, with its median value being $242.6 million (2025).
  • As far as peak fluctuations go, Fulcrum Therapeutics' Liabilities and Shareholders Equity surged by 8135.93% in 2021, and later plummeted by 2756.98% in 2024.
  • Quarter analysis of 5 years shows Fulcrum Therapeutics' Liabilities and Shareholders Equity stood at $235.0 million in 2021, then dropped by 3.54% to $226.7 million in 2022, then grew by 13.68% to $257.7 million in 2023, then grew by 1.17% to $260.7 million in 2024, then fell by 17.59% to $214.9 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $214.9 million for Q3 2025, versus $228.8 million for Q2 2025 and $242.6 million for Q1 2025.